JP2002539805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539805A5 JP2002539805A5 JP2000607471A JP2000607471A JP2002539805A5 JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5 JP 2000607471 A JP2000607471 A JP 2000607471A JP 2000607471 A JP2000607471 A JP 2000607471A JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- dendritic
- tumor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 56
- 238000000034 method Methods 0.000 description 32
- 210000004443 dendritic cell Anatomy 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28267999A | 1999-03-31 | 1999-03-31 | |
| US09/282,679 | 1999-03-31 | ||
| PCT/US2000/008472 WO2000057705A1 (en) | 1999-03-31 | 2000-03-30 | In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539805A JP2002539805A (ja) | 2002-11-26 |
| JP2002539805A5 true JP2002539805A5 (enExample) | 2007-06-07 |
Family
ID=23082644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000607471A Pending JP2002539805A (ja) | 1999-03-31 | 2000-03-30 | 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的ｔ細胞のインビトロ産生 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1168924A4 (enExample) |
| JP (1) | JP2002539805A (enExample) |
| CN (1) | CN1353575A (enExample) |
| AU (1) | AU4183100A (enExample) |
| CA (1) | CA2367590A1 (enExample) |
| WO (1) | WO2000057705A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169898A1 (en) | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
| ATE388237T1 (de) | 1997-04-15 | 2008-03-15 | Dana Farber Cancer Inst Inc | Dendritische zellhybride |
| AU1141901A (en) * | 1999-10-22 | 2001-04-30 | Peter Leskovar | Cell constructs that are suitable for immunotherapy, the production and the use thereof |
| EP1263928B1 (en) * | 2000-02-11 | 2007-09-26 | Dana-Farber Cancer Institute, Inc. | Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| DE10164819A1 (de) | 2001-11-20 | 2005-05-19 | Deml, Ludwig, Dr. | Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen |
| ES2613957T3 (es) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Anticuerpos contra ERBB2 |
| DE102010037622B4 (de) * | 2010-09-17 | 2012-07-12 | Lophius Biosciences Gmbh | Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie |
| EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
| CN102827826B (zh) * | 2012-09-11 | 2017-07-04 | 赵永祥 | 一种诱导树突状细胞与肿瘤细胞融合的方法 |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| CN104830793A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| US11613725B2 (en) * | 2015-05-08 | 2023-03-28 | Wilson Wolf Manufacturing | Culture methods and devices for testing |
| CA2991212A1 (en) | 2015-07-02 | 2017-01-05 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for combination therapy with dengue virus and dendritic cells |
| US10765727B2 (en) | 2015-09-26 | 2020-09-08 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
| CN105532575A (zh) * | 2016-01-14 | 2016-05-04 | 中国科学院昆明动物研究所 | 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用 |
| CN110139671A (zh) | 2016-11-16 | 2019-08-16 | 普莱瓦克斯免疫肿瘤学公司 | 用于治疗癌症的组合免疫疗法 |
| EP3565567A4 (en) | 2017-01-04 | 2020-07-29 | Primevax Immuno-Oncology, Inc. | COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0839044B1 (en) * | 1995-03-31 | 2005-05-18 | Universite Libre De Bruxelles | Dendritic-like cell/tumor cell hybrids for inducing an anti-tumor response |
| ATE388237T1 (de) * | 1997-04-15 | 2008-03-15 | Dana Farber Cancer Inst Inc | Dendritische zellhybride |
| EP1071436A4 (en) * | 1998-01-26 | 2003-08-27 | Dana Farber Cancer Inst Inc | IMMUNE EFFECTOR CELL HYBRIDS |
-
2000
- 2000-03-30 CN CN00808298A patent/CN1353575A/zh active Pending
- 2000-03-30 EP EP00921528A patent/EP1168924A4/en not_active Withdrawn
- 2000-03-30 WO PCT/US2000/008472 patent/WO2000057705A1/en not_active Ceased
- 2000-03-30 AU AU41831/00A patent/AU4183100A/en not_active Abandoned
- 2000-03-30 JP JP2000607471A patent/JP2002539805A/ja active Pending
- 2000-03-30 CA CA002367590A patent/CA2367590A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539805A5 (enExample) | ||
| EP1567014B1 (en) | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors | |
| Heemskerk et al. | Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells | |
| US9694059B2 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| JP2002539805A (ja) | 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的ｔ細胞のインビトロ産生 | |
| Abdel-Wahab et al. | Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity | |
| CN108026513A (zh) | 树突状细胞的抗原加载的方法和疫苗 | |
| Wang et al. | An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens | |
| JP6602377B2 (ja) | 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途 | |
| JP2012219062A (ja) | 細胞傷害性ｔ細胞誘導用組成物 | |
| Mason et al. | RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma | |
| US20030082163A1 (en) | Fused cells, methods of forming same, and therapies utilizing same | |
| CN115698270A (zh) | 一种通过iPS细胞生产再生T细胞的方法 | |
| US20250122473A1 (en) | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same | |
| CN117157391A (zh) | 由用于导入T细胞受体基因的iPS细胞构成的细胞库 | |
| Nair et al. | RNA-transfected dendritic cells | |
| JP2002500872A5 (enExample) | ||
| EP1178822B1 (en) | Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells | |
| US20050170503A1 (en) | In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens | |
| Plautz et al. | Considerations on clinical use of T cell immunotherapy for cancer | |
| NZ508936A (en) | Method for preparation and in vivo administration of antigen presenting cell composition | |
| US20100291683A1 (en) | Modified Antigen Presenting Cells and Methods of Use | |
| CN118221773B (zh) | 与HLA相关的CMV pp65表位疫苗组合物与应用 | |
| WO1998021314A2 (en) | Method of promoting b-cell proliferation and activation and of modulating the immune system | |
| WO2020164167A1 (zh) | 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用 |